Jardiance Price Increase 2026: Tariff Impact and Cheaper Alternatives
Jardiance faces a 100% import tariff starting July 31, 2026 — projected monthly cost rises to $917 (likely) or $1,222 (worst case). Here's your alternatives playbook.
Jardiance (empagliflozin) is one of the most-prescribed SGLT-2 inhibitors in America, used for Type 2 diabetes and heart failure. It's made by Boehringer Ingelheim in Germany — squarely in the path of the 100% pharmaceutical tariff effective July 31, 2026. Here's exactly how much more Jardiance will cost, what your alternatives are, and how Medicare's 2026 price negotiation interacts with the tariff.
Jardiance Tariff Impact at a Glance
| Fact | Value |
|---|---|
| Manufacturer | Boehringer Ingelheim |
| Manufacturing country | Germany |
| Annex III company? | Yes — tariff effective July 31, 2026 |
| Current retail (monthly) | ~$611 |
| Current typical copay | $35-47 |
| Medicare-negotiated price (2026) | $197.54/month (for Part D enrollees) |
| Conservative projected retail | $794/month |
| Likely projected retail | $917/month |
| Worst case projected retail | $1,222/month |
The Medicare Negotiation Twist
Jardiance is one of the first 10 drugs with Medicare-negotiated prices effective January 2026. This creates a complex situation:
- Medicare Part D enrollees pay the negotiated price: $197.54/month
- Commercial insurance patients pay whatever their insurer negotiates (typically current retail)
- Uninsured patients face the full retail price
The tariff adds an additional 100% duty on Boehringer's wholesale import cost. This creates tension:
| Patient Type | Current Monthly | After July 31 Tariff (likely) |
|---|---|---|
| Medicare Part D | $197.54 (negotiated) | $197.54 (contractually fixed) — but Boehringer absorbs tariff |
| Commercial insurance (Tier 3) | $45-60 copay | $50-100+ copay (likely increase) |
| Uninsured | ~$611 cash | ~$917 cash |
Key insight: Medicare enrollees are likely protected by the contractually negotiated price. Commercial and cash patients bear the tariff impact.
Will Boehringer Absorb or Pass Through?
Boehringer Ingelheim faces a specific problem with Jardiance:
- Medicare negotiated price is fixed by contract — can't raise it
- Tariff adds 100% to import cost — can't avoid it
- Commercial market pricing has more flexibility
Industry analysts expect Boehringer to:
- Absorb the tariff impact on Medicare volume (contract obligation)
- Pass through a portion to commercial/cash market (30-75% passthrough likely)
- Consider US manufacturing expansion (long-term hedge)
- Potentially sign a broader deal with the administration to exempt Jardiance
Boehringer has reportedly initiated deal negotiations with the administration. A deal could exempt Jardiance entirely.
Three Scenarios: What You'll Actually Pay
Scenario A: Medicare Part D Enrollee
You're protected. The negotiated price of $197.54/month remains in effect through 2026. Your out-of-pocket cost:
- Before $2,000 Medicare OOP max: $20-40/month depending on coverage phase
- After OOP max: $0 for remainder of year
The tariff does NOT change what you pay for Jardiance.
Scenario B: Commercial Insurance (Tier 3 formulary, $45 copay)
Your copay may increase, but your insurance absorbs most of the tariff impact:
| Timeline | Retail Price | Your Copay |
|---|---|---|
| April 2026 | $611 | $45 |
| August 2026 (likely) | $917 | $50-75 (tier bump possible) |
| August 2026 (worst) | $1,222 | $75-150 (coinsurance possible) |
Scenario C: Uninsured / Cash-Pay
You bear the full tariff impact:
| Timeline | Cash Retail Price |
|---|---|
| April 2026 | $611/month |
| August 2026 (likely) | $917/month (+$306) |
| August 2026 (annual impact) | +$3,672/year |
Alternative cash-pay options for uninsured patients:
- GoodRx/Mark Cuban Cost Plus Drugs — ~$450/month today (may also rise)
- Manufacturer patient assistance program — free if income-qualified
- Generic alternative (see below) — much cheaper
Jardiance Alternatives After the Tariff
Clinically Similar SGLT-2 Inhibitors
| Drug | Manufacturer | Country | Tariff Status | Current Monthly Retail |
|---|---|---|---|---|
| Jardiance (empagliflozin) | Boehringer | Germany | Affected | ~$611 |
| Farxiga (dapagliflozin) | AstraZeneca | Sweden | Affected | ~$610 |
| Invokana (canagliflozin) | J&J | Ireland | Affected | ~$710 |
| Steglatro (ertugliflozin) | Merck | US | Exempt | ~$590 |
Steglatro is the only US-made SGLT-2 inhibitor — and therefore exempt from the tariff. After July 31, 2026:
- Jardiance: ~$917 (likely)
- Farxiga: ~$915 (likely)
- Invokana: ~$1,065 (likely)
- Steglatro: ~$590 (unchanged) — projected cheapest option
Steglatro is less prescribed than Jardiance/Farxiga, so not every insurer covers it well. Ask your doctor.
Different Drug Class Alternatives
For Type 2 diabetes, other drug classes can substitute for Jardiance:
| Class | Example | US-made? | Notes |
|---|---|---|---|
| GLP-1 (weekly injection) | Mounjaro, Trulicity | Yes | More expensive but more effective; exempt from tariff |
| DPP-4 inhibitor | Januvia | No | Generic sitagliptin launches May 2026 — exempt |
| Metformin | generic | N/A (generic) | Cheapest; first-line drug |
| Insulin | varies | mixed | $35 Medicare cap applies |
For heart failure (one of Jardiance's major indications), the primary alternatives are:
| Drug | Manufacturer | Country | Tariff Status |
|---|---|---|---|
| Entresto | Novartis | Switzerland | Affected |
| Farxiga | AstraZeneca | Sweden | Affected |
| Kerendia | Bayer | Germany | Affected |
Unfortunately, most heart failure drugs are imported. Generic candesartan (for hypertension/heart failure) is a cheap generic alternative, though clinically different.
Generic Empagliflozin: The Ultimate Exemption
Generic empagliflozin is expected to launch in 2027 after patent expiration. When it launches:
- Generic empagliflozin will be exempt from the tariff (all generics are)
- Price typically drops 80-90% vs brand in first year
- By 2028, generic empagliflozin may cost $50-100/month
If you can bridge 12-18 months with Jardiance or an alternative, generic will dramatically improve costs.
Stockpiling Jardiance Before July 31
If you expect to continue Jardiance through the tariff period, consider:
- Ask for a 90-day supply — most maintenance insurance plans allow this
- Mail-order through your insurance — often cheaper per-pill than retail
- Check refill timing — if you refill in late July 2026, you lock in pre-tariff pricing for 30-90 days
Don't exceed your prescription. You can't legally get more than your prescription allows. But timing your refill to just before the tariff effective date is legal and smart.
What About Commercial Patient Assistance Programs?
Boehringer Ingelheim offers the Jardiance Savings Card for commercially insured patients: as low as $10/month copay for eligible patients. Check eligibility at jardiance.com.
Important caveats:
- Not available for Medicare, Medicaid, or uninsured patients
- Annual benefit limit applies
- Manufacturer can change terms
Frequently Asked Questions
I'm on Medicare — will my Jardiance copay actually go up?
Probably not meaningfully. Medicare Part D enrollees get the negotiated $197.54/month price, and the new $2,000 annual out-of-pocket max limits your total exposure. The tariff burden falls on Boehringer, not on Medicare patients.
Can I just switch to Steglatro?
Talk to your doctor. Steglatro is clinically similar but has less real-world evidence than Jardiance for heart failure specifically. For diabetes-only use, Steglatro is a reasonable alternative. For patients with heart failure with reduced ejection fraction (HFrEF), Jardiance and Farxiga have stronger evidence.
Is Farxiga also affected?
Yes. Farxiga is made by AstraZeneca in Sweden — same tariff situation as Jardiance. Both will become more expensive after July 31, 2026 for commercial/cash patients.
Will Jardiance be exempt if Boehringer makes a deal?
Possibly. Boehringer is reportedly in negotiations with the administration. A pricing or onshoring deal could exempt Jardiance from the tariff. Monitor announcements through mid-2026.
What about generic empagliflozin?
Patent protection for empagliflozin runs through 2025-2028 depending on the specific claim. Generic versions are expected to launch in 2027. When they do, they'll be exempt from the tariff and dramatically cheaper.
Conclusion
Jardiance's tariff situation depends heavily on your insurance status. Medicare Part D enrollees are contractually protected at $197.54/month. Commercial insurance patients should expect modest copay increases. Uninsured/cash patients face the full impact — $306-611/month increases depending on Boehringer's passthrough decision. Switching to US-made Steglatro is the cleanest tariff-avoidance alternative for SGLT-2 use. Check your specific Jardiance impact here.